Dear readers,
We are glad to announce of our new website, There you will continue to have access to the full content of the Sharecast newswire, alongside an improved and expanded suite of market data and research tools for both the UK and the main international markets. As a first step in the transition to the new site, over coming days and weeks the news and data pages on will redirect you towards the new website which we earnestly hope you will find even more useful than the current service. Should anyone like to comment or provide constructive criticism on the new layout or what features they would like to see added or deleted, do please send us an e-mail to Lastly, of course, we wish to express our heartfelt gratitude for your support and encouragement over the years as we continued to grow and expand the service.
Very best,


Danaher to acquire Cepheid in $4bn deal


Danaher to acquire Cepheid in $4bn deal

Tue, 06 September 2016
Article viewed 133 times
Danaher to acquire Cepheid in $4bn deal
Danaher Corp. Quote more

Price: 90.06

Chg: 4.01

Chg %: 4.66%

Date: 13:49

S&P 500 Quote

Price: 2,558.74 Chg: -0.62 Chg %: -0.02% Date: 13:55

(ShareCast News) - US manufacturing company Danaher Corp. is set to buy molecular diagnostics firm Cepheid in a deal worth around $4bn including debt.
Danaher has agreed to pay Cepheid $53 per share in cash, and the transaction is expected to be completed by the fourth quarter.

All outstanding shares of Cepheid will be acquired by Danaher, according to a statement released on Tuesday.

John Bishop, chairman and CEO of Cepheid, said that the company will be able thrive as part of Danaher.

"Looking forward as a part of Danaher and its $5 billion Diagnostics platform, we believe that Cepheid will be able to reach an extended level of customers and patients more quickly than we could have on a standalone basis," Bishop said.

The company posted revenue of $539m last year, which could rise to $635m this year, according to Danaher.

Cepheid's board unanimously approved the agreement, which is subject to shareholder approval and clearances by the relevant regulatory authorities.